Cognivia, a Mont-Saint-Guibert, Belgium-based AI company focused on pharmaceutical and biotech research, has secured €15.5M in funding.

The round was led by Vesalius Biocapital IV, with participation from SFPIM and WE. The funds will be used to accelerate the deployment of Cognivia's predictive clinical trial solutions, which leverage AI and machine learning to decode the relationship between patient traits and behaviors.

CEO Dominique Demolle remarked, “This investment, coupled with the addition of new team members and advisors, positions us to enhance our innovative approaches, benefiting clinicians and patients worldwide.”

Cognivia integrates psychological data and AI to improve therapeutic efficacy measurements in clinical trials, aiming to expedite the development of new treatments globally. The company's unique technologies predict patient behavior and treatment responses using specially developed questionnaires and advanced ML algorithms.